Abstract
Anaplastic thyroid cancer (ATC) is the most aggressive type of thyroid cancer (TC) and has the lowest survival rate, 6 to 18 months. Treatment options are limited due to iodine non-uptake and acquisition of resistance, mainly to the tyrosine kinase inhibitors, such as MAPK and PI3K/AKT/mTOR pathways inhibitors. The JAK/STAT signaling pathway in ATC has been associated with the development…